The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.
2025
New cancer vaccine method boosts potency and scope
Vaccines to treat cancers have been around since 2010, the first being approved for prostate cancer, and another in 2015 for melanoma.
Eikon Adds Nearly $351M to Conquer Phase III Development in Melanoma
Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise.
Melanoma risk doubles among childhood cancer survivors
Childhood cancer survivors are more than twice as likely to develop melanoma as the general population, according to findings published in Journal of Clinical Oncology.